35 completed, 8 terminated, 8 unknown. 51 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 51 | Completed 35, Terminated 8, Unknown 8 |
Follow Lopinavir: new trials by email Literature Review of Lopinavir trials Research Report on Lopinavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients Remdesivir, Lopinavir/ Ritonavir and Remdesivir combination - Covid19 | Phase 4 | Unknown | Ahmed Essam | 90 | 2020-11-01 | 2021-03-17 |
| Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients. Remdesivir, Hydroxychloroquine, Tocilizumab - Covid19, Pneumonia | Phase 4 | Unknown | October 6 University | 150 | 2020-10-01 | 2021-03-17 |
| Interferon Beta 1a in Hospitalized COVID-19 Patients Interferon Beta-1A, Lopinavir / Ritonavir, Single Dose of Hydroxychloroquine - COVID-19 | Phase 4 | Unknown | Shahid Beheshti University of Medical Sciences | 40 | 2020-04-15 | 2020-04-20 |
| Umifenovir in Hospitalized COVID-19 Patients Umifenovir, Interferon-β 1a, Lopinavir / Ritonavir - COVID-19 | Phase 4 | Unknown | Shahid Beheshti University of Medical Sciences | 40 | 2020-04-15 | 2020-04-20 |
| The Clinical Study of Carrimycin on Treatment Patients With COVID-19 Carrimycin, lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate, basic treatment - Novel Coronavirus Infectious Disease (COVID-19) | Phase 4 | Unknown | Beijing YouAn Hospital | 520 | 2020-02-23 | 2020-02-27 |
| A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir - 2019-nCoV | Phase 4 | Unknown | Tongji Hospital | 400 | 2020-02-01 | 2020-03-17 |
| The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection Lopinavir and Ritonavir Tablets, Arbidol - Coronavirus Infections | Phase 4 | Completed | Guangzhou 8th People's Hospital | 86 | 2020-01-28 | 2020-07-01 |
| Antiretroviral Regime for Viral Eradication in Newborns Zidovudine, Nevirapine, Lamivudine - HIV/AIDS and Infections | Phase 4 | Completed | National Center for Women and Children's Health, China CDC | 600 | 2016-04-01 | 2022-09-28 |
| IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children ZDV+3TC+LPV/r - HIV Positive, Malnourished | Phase 4 | Completed | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 52 | 2015-10-26 | 2021-08-12 |
| HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen Dolutegravir, PI, 2 NRTI - HIV-1 | Phase 4 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 44 | 2015-06-01 | 2017-06-14 |
| Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB lopinavir with ritonavir in 1:1 ratio, Lopinavir/ritonavir 4:1 - Acquired Immunodeficiency Syndrome, Tuberculosis | Phase 4 | Completed | Drugs for Neglected Diseases | 96 | 2013-01-01 | 2017-05-11 |
| Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) 8 hourly LPV/r during TB treatment, Nevirapine, Lopinavir/Ritonavir - Tuberculosis, HIV | Phase 4 | Completed | University of Cape Town | 200 | 2012-11-01 | 2017-10-27 |
| MARCH Renal Substudy arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors, Arm 2 boosted protease inhibitors and maraviroc, Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc - Proteinuria, HIV | Phase 4 | Completed | Kirby Institute | 76 | 2012-06-01 | 2016-01-20 |
| Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily Lopinavir/ritonavir 800 mg / 200mg - HIV | Phase 4 | Completed | Daniel Podzamczer | 21 | 2012-05-01 | 2016-10-06 |
| Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy Lumbar puncture (Lopinavir/ritonavir monotherapy), Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI) - HIV | Phase 4 | Completed | Germans Trias i Pujol Hospital | 35 | 2010-08-01 | 2019-12-05 |
| Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) lopinavir/ritonavir plus maraviroc - HIV Infections | Phase 4 | Terminated | Temple University | 1 | 2010-04-01 | 2020-11-02 |
| Bone and Body Comp: A Sub Study of the SECOND-LINE Study Lopinavir / ritonavir, 2-3N(t)RTI, raltegravir - HIV | Phase 4 | Completed | Kirby Institute | 210 | 2010-02-01 | 2025-06-26 |
| Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin Pitavastatin (NK-104), Lopinavir/ritonavir - Healthy Volunteers | Phase 4 | Completed | Kowa Research Institute, Inc. | 24 | 2010-01-01 | 2021-06-22 |
| Pilot Assessment of Lopinavir/Ritonavir and Maraviroc lopinavir/ritonavir plus maraviroc - HIV Infections, Acquired Immunodeficiency Syndrome | Phase 4 | Terminated | Rodwick, Barry M., M.D. | 3 | 2009-12-01 | 2015-06-23 |
| Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens Darunavir/ritonavir, Lopinavir/ritonavir - HIV Infections | Phase 4 | Completed | Germans Trias i Pujol Hospital | 73 | 2009-10-01 | 2014-02-13 |
Showing 20 of 51. Sign in to see all of them.
HIV Infections (27) · Acquired Immunodeficiency Syndrome (11) · COVID-19 (5) · Tuberculosis (3) · Lipodystrophy (2) · AIDS-Related Opportunistic Infections (1) · Breast Feeding (1) · Cardiovascular Diseases (1) · Coronavirus Infections (1) · Disease Progression (1) · Dyslipidemias (1) · Glucose Metabolism Disorders (1) · HIV Seropositivity (1) · HIV-Associated Lipodystrophy Syndrome (1) · Hepatitis C (1)
Germans Trias i Pujol Hospital (3) · Kirby Institute (3) · AbbVie (prior sponsor, Abbott) (2) · Fundacion SEIMC-GESIDA (2) · Juan A. Arnaiz (2) · Oswaldo Cruz Foundation (2) · Shahid Beheshti University of Medical Sciences (2) · Abbott (1) · Ahmed Essam (1) · Allina Health System (1) · Amsterdam UMC, location VUmc (1) · Beijing YouAn Hospital (1) · Daniel Podzamczer (1) · Drugs for Neglected Diseases (1) · Emory University (1)
United States (15) · Spain (11) · South Africa (5) · Argentina (3) · Canada (3) · China (3) · Mexico (3) · United Kingdom (3) · Australia (2) · Brazil (2) · Egypt (2) · Iran (2) · Malawi (2) · Puerto Rico (2) · Thailand (2)
Ilad Alavi Darazam, MD (2) · Minoosh Shabani, MD (2) · Mohammadreza Haji Esmaelie, MD (2) · Seyed Sina Naghibi Irvani, MD, MPH, MBA (2) · Shervin Shokouhi, MD (2) · Allan R. Tenorio, M.D. (1) · Andrew D Carr, MD (1) · Andrew R. Zolopa, MD (1) · Andrew Ratsela, MD (1) · Barry M. Rodwick, M. D. (1) · Beatriz J Grinsztejn, MD (1) · Brookie Best, PharmD, MAS (1) · Carl J Fichtenbaum, MD (1) · Carlos R Rivera-Vazquez, MD (1) · Daniel Podzamczer, MD (1)
PMID 37988391, PMID 19275490, PMID 19424051, PMID 19440326, PMID 19479079, PMID 19898246, PMID 19906626, PMID 19967342, PMID 20455766, PMID 20617176, PMID 20942650, PMID 21054216, PMID 21126955, PMID 21716078, PMID 21886816, PMID 22364141, PMID 22448211, PMID 22627182, PMID 23383047, PMID 23386261, PMID 23921615, PMID 24204757, PMID 24614377, PMID 25155608, PMID 25386736, PMID 25831464, PMID 26810651, PMID 27815068, PMID 29683854, PMID 30529029, PMID 31081020, PMID 32071055, PMID 32838353, PMID 33464021, PMID 34273635, PMID 34764044, PMID 37919816
2008 (1), U01AI068632 (1)